Hydrophilic bile acids: Prevention and dissolution experiments in two animal models of cholesterol cholelithiasis-Reference-Cited by-同舟云学术

Hydrophilic bile acids: Prevention and dissolution experiments in two animal models of cholesterol cholelithiasis

Published:1995-09 Issue:9 Volume:30 Page:855-861
ISSN:0024-4201
Container-title:Lipids
language:en
Short-container-title:Lipids

Author:

Cohen Bertram I.,Mikami Takahiro,Ayyad Nariman,Ohshima Akira,Infante R.,Mosbach Erwin H.

Publisher

Wiley

Subject

Cell Biology,Organic Chemistry,Biochemistry

Reference34 articles.

1. Danzinger, R.G., Hofmann, A.F., Schoenfield, L.J., and Thistle, J.L. (1972) Dissolution of Cholesterol Gallstones by Chenodeoxycholic Acid,N. Engl. J. Med. 286, 1–8.

2. Nakagawa, S., Makino, I., Ishizaki, T., and Dohi, I. (1977) Dissolution of Cholesterol Gallstones by Ursodeoxycholic AcidLancet 2, 367–369.

3. Northfield, T.C., Jazrawi, R.P., and Petroni, M.L. (1990) Medical Dissolution Therapy, inStrategies for the Treatment of Hepatobiliary Diseases (Paumgartner, G., Stiehl, A., Barbara, L., and Roda, E., eds.) pp. 163–184, Kluwer Academic Publishers, The Netherlands.

4. Fromm, H.M., and Malavolti, M. (1988) Dissolving Gallstones,Adv. Intern. Med. 33, 409–430.

5. Hofmann, A.F., Thistle, J.L., Klein, P.D., Szczepanski, P.A., and Yu, P.Y.S. (1978) Chenotherapy for Gallstone Dissolution. II. Induced Changes in Bile Composition and Gallstone Response,JAMA 239, 1138–1144.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of barley variety, dietary fiber and β-glucan content on bile acid composition in cecum of rats fed low- and high-fat diets;The Journal of Nutritional Biochemistry;2018-03

2. Gall Bladder Function;Drug Discovery and Evaluation: Pharmacological Assays;2016

3. Gallbladder Function;Drug Discovery and Evaluation: Pharmacological Assays;2014

4. Species-Specific and Age-Dependent Bile Acid Composition: Aspects on CYP8B and CYP4A Subfamilies in Bile Acid Biosynthesis;Current Drug Metabolism;2008-05-01

5. Activity on the Gastrointestinal Tract;Drug Discovery and Evaluation;2007